Denmark

Key Insights

1
No psychedelic therapy is approved for routine patient use in Denmark; access is confined to hospital-led research, while esketamine is the only ketamine-class medicine in mainstream psychiatry.
2
Denmark has 12 psychedelic-related trials, 7 active, across 7 organisations; psilocybin leads, with LSD and esketamine also in active studies.
3
Denmark’s modern psychedelic pedigree runs deep: Frederiksberg Hospital treated 324 LSD and psilocybin cases from 1960 to 1973.
4
Momentum is centred on the University of Copenhagen’s NOESIS clinic and PsyPal, the first EU-funded multi-site psilocybin trial, with Danish patient recruitment underway.

Medical Only (Private)

Reimbursed Care Access

Denmark currently permits regulated medical use of esketamine (Spravato) within the health system with hospital-based delivery and no automatic outpatient pharmacy subsidy; ketamine is used off‑label in specialist and research settings. Classic psychedelics (psilocybin, MDMA) are accessible only via approved clinical trials or research projects; classical entheogens and many tryptamines/phenethylamines (DMT, 5‑MeO‑DMT, ibogaine, mescaline, 2C‑X) remain controlled or functionally illegal for recreational/medical use outside research, though plant decoctions like ayahuasca occupy a legal gray area because plant material is not always separately scheduled even when constituent DMT is banned.

Full guide →